JOURNAL ARTICLE

Preclinical Proof of Concept Studies for Rare Diseases (NCATS/NIMH).

  • Published In: Federal Grants & Contracts, 2023, v. 47, n. 16. P. 7 1 of 2

  • Database: Business Source Ultimate 2 of 2

Abstract

B Scope: b The National Center for Advancing Translational Sciences and the National Institute of Mental Health seek applications for the Preclinical Proof of Concept Studies for Rare Diseases announcement to conduct efficacy studies in an established rare disease preclinical model to demonstrate that a proposed therapeutic agent warrants further development. B Areas: b NCATS/NIMH said the goal of this announcement is to spur therapeutic development for rare diseases by advancing projects to the point where they would attract subsequent investment supporting full Investigational New Drug (IND) application development or progression to clinical trials in the case of repurposing or repositioning. [Extracted from the article]

Additional Information

  • Source:Federal Grants & Contracts. 2023/07, Vol. 47, Issue 16, p7
  • Document Type:Article
  • Subject Area:Health and Medicine
  • Publication Date:2023
  • ISSN:1949-3177
  • DOI:10.1002/fgc.33154
  • Accession Number:165047240
  • Copyright Statement:Copyright of Federal Grants & Contracts is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Looking to go deeper into this topic? Look for more articles on EBSCOhost.